<code id='25D48A8F3E'></code><style id='25D48A8F3E'></style>
    • <acronym id='25D48A8F3E'></acronym>
      <center id='25D48A8F3E'><center id='25D48A8F3E'><tfoot id='25D48A8F3E'></tfoot></center><abbr id='25D48A8F3E'><dir id='25D48A8F3E'><tfoot id='25D48A8F3E'></tfoot><noframes id='25D48A8F3E'>

    • <optgroup id='25D48A8F3E'><strike id='25D48A8F3E'><sup id='25D48A8F3E'></sup></strike><code id='25D48A8F3E'></code></optgroup>
        1. <b id='25D48A8F3E'><label id='25D48A8F3E'><select id='25D48A8F3E'><dt id='25D48A8F3E'><span id='25D48A8F3E'></span></dt></select></label></b><u id='25D48A8F3E'></u>
          <i id='25D48A8F3E'><strike id='25D48A8F3E'><tt id='25D48A8F3E'><pre id='25D48A8F3E'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:82
          Johnson & Johnson logo. -- health coverage from STAT.
          Chris O'Meara/AP

          Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

          Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

          advertisement

          In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          CRISPR gene editing developments we’re watching in 2024
          CRISPR gene editing developments we’re watching in 2024

          ChristineKao/STATLifeintheCRISPRlanetendstomoveatlightningspeed.Thisyearsawthefirst-everapprovalofam

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          How to keep neuroscience’s past racism from being its future

          De-ShaineMurrayisworkingatthecuttingedgeofneurotechnology.AsapostdoctoralfellowatYale,heisdeveloping